Patrick W B Derksen

List of Publications by Year
in descending order

58 papers	5,109 citations	126708 33 h-index	161609 54 g-index
62 all docs	62 docs citations	62 times ranked	8046 citing authors

#	Article	IF	Citations
1	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). Cancer Research, 2022, 82, P1-02-09-P1-02-09.	0.4	0
2	Abstract P1-19-02: Repurposing the FOXO4 senolytic against triple-negative breast cancer. Cancer Research, 2022, 82, P1-19-02-P1-19-02.	0.4	0
3	Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment. Oncogene, 2022, 41, 2458-2469.	2.6	47
4	FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer. Cell Reports, 2022, 39, 110584.	2.9	4
5	Interâ€observer agreement for the histological diagnosis of invasive lobular breast carcinoma. Journal of Pathology: Clinical Research, 2022, 8, 191-205.	1.3	19
6	Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. Oncogene, 2022, 41, 2932-2944.	2.6	10
7	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. Cancers, 2021, 13, 3695.	1.7	35
8	Abstract LB246: E-cadherin loss drives Id2-dependent dampening of cell cycle progression and predicts increased susceptibility to CDK4/6 inhibition in lobular breast cancer. , 2021, , .		0
9	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. Cancers, 2021, 13, 5396.	1.7	17
10	Shared mechanisms regulate spatiotemporal RhoA-dependent actomyosin contractility during adhesion and cell division. Small GTPases, 2020, 11, 113-121.	0.7	6
11	E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. Modern Pathology, 2020, 33, 2483-2498.	2.9	26
12	FOXO Transcription Factors Both Suppress and Support Breast Cancer Progression. Cancer Research, 2018, 78, 2356-2369.	0.4	61
13	Variants in members of the cadherinâ€“catenin complex, CDH1 and CTNND1, cause blepharocheilodontic syndrome. European Journal of Human Genetics, 2018, 26, 210-219.	1.4	34
14	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Cancer Discovery, 2018, 8, 498-515.	7.7	79
15	Loss of E-Cadherin-Dependent Cellâ€“Cell Adhesion and the Development and Progression of Cancer. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029330.	2.3	142
16	Re-evaluating the role of FOXOs in cancer. Seminars in Cancer Biology, 2018, 50, 90-100.	4.3	136
17	E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. Scientific Reports, 2018, 8, 15454.	1.6	55
18	Î±Eâ€catenin is a candidate tumor suppressor for the development of Eâ€cadherinâ€expressing lobularâ€type breast cancer. Journal of Pathology, 2018, 245, 456-467.	2.1	34

#	Article	IF	Citations
19	Re-inforcing the cell death army in the fight against breast cancer. Journal of Cell Science, 2018, 131, .	1.2	14
20	Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis. ELife, 2018, 7, .	2.8	32
21	Intraductal cisplatin treatment in a <i>BRCA</i>-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget, 2017, 8, 60750-60763.	0.8	11
22	Prophylaxis of hereditary breast cancer. Aging, 2017, 9, 2453-2454.	1.4	0
23	Mesenchymal Cell Invasion Requires Cooperative Regulation of Persistent Microtubule Growth by SLAIN2 and CLASP1. Developmental Cell, 2016, 39, 708-723.	3.1	69
24	p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis. Nature Communications, 2016, 7, 13874.	5.8	17
25	p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice. Journal of Mammary Gland Biology and Neoplasia, 2016, 21, 81-88.	1.0	12
26	Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer. Molecular Imaging and Biology, 2016, 18, 535-544.	1.3	54
27	Nuclear p120-catenin contributes to anoikis resistance of Lobular Breast Cancer through Kaiso-dependent Wnt11 expression. DMM Disease Models and Mechanisms, 2015, 8, 373-84.	1.2	29
28	Lobular breast cancer: molecular basis, mouse and cellular models. Breast Cancer Research, 2015, 17, 16.	2.2	48
29	Methylation biomarkers for pleomorphic lobular breast cancer - a short report. Cellular Oncology (Dordrecht), 2015, 38, 397-405.	2.1	10
30	Lobular Breast Cancer: Pathology, Biology, and Options for Clinical Intervention. Archivum Immunologiae Et Therapiae Experimentalis, 2014, 62, 7-21.	1.0	19
31	Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma In Situ with CD44v6-Specific Antibodies in Mice: A Preclinical Study. Molecular Imaging and Biology, 2013, 15, 290-298.	1.3	9
32	Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cellular Oncology (Dordrecht), 2013, 36, 375-384.	2.1	69
33	p120-catenin in cancer â€“ mechanisms, models and opportunities for intervention. Journal of Cell Science, 2013, 126, 3515-3525.	1.2	75
34	Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling. Cancer Research, 2013, 73, 4937-4949.	0.4	47
35	p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast. Cellular Oncology (Dordrecht), 2012, 35, 111-118.	2.1	16
36	Nuclear Kaiso Expression Is Associated with High Grade and Triple-Negative Invasive Breast Cancer. PLoS ONE, 2012, 7, e37864.	1.1	45

#	Article	IF	Citations
37	Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids. Cancer Cell, 2011, 20, 370-383.	7.7	279
38	Chemotherapy Enhances Metastasis Formation via VEGFR-1â€“Expressing Endothelial Cells. Cancer Research, 2011, 71, 6976-6985.	0.4	146
39	Intravital microscopy: new insights into metastasis of tumors. Journal of Cell Science, 2011, 124, 299-310.	1.2	132
40	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. DMM Disease Models and Mechanisms, 2011, 4, 347-358.	1.2	119
41	Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. Journal of Clinical Investigation, 2011, 121, 3176-3188.	3.9	113
42	A tissue reconstitution model to study cancer cellâ€intrinsic and â€extrinsic factors in mammary tumourigenesis. Journal of Pathology, 2010, 220, 34-44.	2.1	13
43	Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells. Gastroenterology, 2010, 138, 2357-2367.	0.6	130
44	NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO Journal, 2008, 27, 2603-2615.	3.5	167
45	Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin. Clinical Cancer Research, 2008, 14, 3916-3925.	3.2	299
46	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17079-17084.	3.3	854
47	Models for angiogenesis: From fundamental mechanisms to anticancer treatment research. Drug Discovery Today: Disease Models, 2007, 4, 75-82.	1.2	0
48	Modeling Metastatic Breast Cancer in Mice. Journal of Mammary Gland Biology and Neoplasia, 2007, 12, 191-203.	1.0	55
49	Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood, 2006, 107, 760-768.	0.6	80
50	Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell, 2006, 10, 437-449.	7.7	522
51	Follicular Dendritic Cells Catalyze Hepatocyte Growth Factor (HGF) Activation in the Germinal Center Microenvironment by Secreting the Serine Protease HGF Activator. Journal of Immunology, 2005, 175, 2807-2813.	0.4	24
52	Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6122-6127.	3.3	293
53	Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4. Journal of Gene Medicine, 2004, 6, 317-327.	1.4	34
54	Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood, 2004, 104, 2172-2175.	0.6	54

#	Article	IF	Citations
55	The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia, 2003, 17, 764-774.	3.3	145
56	Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood, 2002, 99, 1405-1410.	0.6	235
57	Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. Biochemical and Biophysical Research Communications, 2002, 298, 80-86.	1.0	37
58	The hepatocyte growth factor/ met pathway in development, tumorigenesis, and B-cell differentiation. Advances in Cancer Research, 2000, 79, 39-90.	1.9	95